TrialThe New England journal of medicine2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Joaquim Bellmunt et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1,825 papers cite itlatest 60 shown
this paperpooled ittrialcites it